AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11398117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 200 mg twice daily for 3 days (children aged 4-11 years)
Number of subjects: 100
Study 11398117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 100 mg twice daily for 3 days (children aged 1-3 years)
Number of subjects: 100
Study 11398117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11398117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 100
Study 9256993 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 36
Study 9256993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8329476 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 80
Study 8329476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 3442149 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution (Hctr. 29‐27%)
Number of subjects: 100
Study 3442149 — intervention group
Group type: COMPARATOR
Intervention: Non-hemodiluted patients
Number of subjects: 100
Study 29461070 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 70
Study 29461070 — intervention group
Group type: COMPARATOR
Intervention: Standard-care (SC)
Number of subjects: 70
Study 28237854 — intervention group
Group type: EXPERIMENTAL
Intervention: Relamorelin
Number of subjects: 56
Study 28237854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 26250743 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality disorder present
Number of subjects: 366
Study 26250743 — intervention group
Group type: COMPARATOR
Intervention: No personality disorder
Number of subjects: 366
Study 23411400 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional training group
Number of subjects: 71
Study 23411400 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 21907749 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-B (1×10(8) pfu/dose) administered as 3 intramuscular injections at weeks 0, 4, and 16
Number of subjects: 30
Study 21907749 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-B (1×10(8) pfu/dose)
Number of subjects: 30
Study 18462280 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient laparoscopic cholecystectomy (OPS)
Number of subjects: 100
Study 18462280 — intervention group
Group type: COMPARATOR
Intervention: Inpatient laparoscopic cholecystectomy (IPS)
Number of subjects: 100
Study 15940379 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg
Number of subjects: 42
Study 15940379 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 10 mg
Number of subjects: 42
Study 12230484 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin
Number of subjects: 93
Study 12230484 — intervention group
Group type: COMPARATOR
Intervention: Dextrose
Number of subjects: 93
Study 10700784 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine 1.25 mg and fentanyl 25 micrograms (group A)
Number of subjects: 49
Study 10700784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 2.5 mg and fentanyl 25 micrograms (group B)
Number of subjects: 49
Study 7537364 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate therapy
Number of subjects: 57
Study 2037113 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a and hMG for IVF treatment with extended follicle growth by 1 day
Number of subjects: 0
Study 2037113 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard follicle growth duration not specified)
Number of subjects: 0
Study 7125264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1.5 mg/kg)
Number of subjects: 80
Study 7125264 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg/kg)
Number of subjects: 80
Study 7125264 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-Ketamine combination (0.15 mg/kg midazolam and 0.75 mg/kg ketamine)
Number of subjects: 80
Study 7125264 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (4 mg/kg)
Number of subjects: 80
Study 7125264 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 80
Study 31067121 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAMP+ intervention
Number of subjects: 88
Study 31067121 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 88
Study 30882604 — intervention group
Group type: EXPERIMENTAL
Intervention: Firibastat (250 mg b.i.d. for 1 week, uptitrated to 500 mg b.i.d. for 3 weeks)
Number of subjects: 34
Study 30882604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 30882604 — intervention group
Group type: EXPERIMENTAL
Intervention: Firibastat
Number of subjects: 34
Study 28555206 — intervention group
Group type: EXPERIMENTAL
Intervention: Conical connection implants
Number of subjects: 90
Study 28555206 — intervention group
Group type: COMPARATOR
Intervention: Internal hex connection implants
Number of subjects: 90
Study 26686406 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab 10 mg/kg plus lenalidomide (25 mg) and dexamethasone (40 mg)
Number of subjects: 73
Study 26686406 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab 20 mg/kg plus lenalidomide (25 mg) and dexamethasone (40 mg)
Number of subjects: 73
Study 26686406 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab (both dosages)
Number of subjects: 73
Study 26686406 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 73
Study 23764722 — intervention group
Group type: COMPARATOR
Intervention: Increased extra‐axonal axial and radial diffusivities in white matter tracts
Number of subjects: 41
Study 23764722 — intervention group
Group type: COMPARATOR
Intervention: Decreased axonal water fraction
Number of subjects: 41
Study 23764722 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter tract integrity metrics in the body of the corpus callosum
Number of subjects: 41
Study 21434845 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular metal cups (Monoblock cup)
Number of subjects: 60
Study 21434845 — intervention group
Group type: COMPARATOR
Intervention: Titanium fiber-mesh cups (Trilogy cup)
Number of subjects: 60
Study 21434845 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 19747744 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (2 x 400 mg/day)
Number of subjects: 35
Study 19747744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 17038015 — intervention group
Group type: EXPERIMENTAL
Intervention: P-OSCE
Number of subjects: 72
Study 17038015 — intervention group
Group type: COMPARATOR
Intervention: Written Exam
Number of subjects: 72
Study 12626436 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (3 hours of cycling)
Number of subjects: 8
Study 12626436 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-6 infusion (3 hours)
Number of subjects: 8
Study 12626436 — intervention group
Group type: COMPARATOR
Intervention: Control (resting)
Number of subjects: 8
Study 11298543 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir (FCV) 125 mg twice daily for 5 days
Number of subjects: 204
Study 11298543 — intervention group
Group type: COMPARATOR
Intervention: Aciclovir (ACV) 200 mg five times daily for 5 days
Number of subjects: 204
Study 11298543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FCV and ACV
Number of subjects: 204
Study 9402661 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective continuous coronary perfusion via the aortic root with warm esmolol-enriched CPB blood
Number of subjects: 60
Study 9402661 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (Bretschneider HTK)
Number of subjects: 60
Study 8497826 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (5, 10, and 20 mg)
Number of subjects: 11
Study 8497826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2447411 — intervention group
Group type: EXPERIMENTAL
Intervention: SLOx (slow release oxprenolol) administered in a single evening dose for 7 days
Number of subjects: 8
Study 2447411 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 7 days
Number of subjects: 8
Study 30326587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose trifle
Number of subjects: 77
Study 30326587 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose trifle
Number of subjects: 77
Study 27932822 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental hygienist-therapist only for check-up
Number of subjects: 60
Study 27932822 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating between general dental practitioner and dental hygienist-therapist
Number of subjects: 60
Study 27932822 — intervention group
Group type: COMPARATOR
Intervention: General dental practitioner only for check-up
Number of subjects: 60
Study 27932822 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment rate
Number of subjects: 60
Study 27932822 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative study
Number of subjects: 60
Study 24089073 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor metabolizers (PMs)
Number of subjects: 80
Study 24089073 — intervention group
Group type: COMPARATOR
Intervention: Extensive metabolizers (EMs)
Number of subjects: 80
Study 24089073 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 23488887 — intervention group
Group type: EXPERIMENTAL
Intervention: Social prompting intervention
Number of subjects: 0
Study 23488887 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling intervention
Number of subjects: 0
Study 23488887 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 0
Study 21178422 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guidance for antibiotic therapy
Number of subjects: 0
Study 18005195 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EG) - 3 cups of Clinutren fruit, 2 boxes of OPD Elemental 028 extra, 2 cups of OPD Peptamen, 1000 ml isotonic cristalloid solution, allowed to drink up to 1000 ml of tea or water per 24 h
Number of subjects: 32
Study 18005195 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (PG) - 1250 ml Nutriflex lipid basal intravenously, 1000 ml isotonic cristalloid solution, allowed to drink up to 1000 ml of tea or water per 24 h
Number of subjects: 32
Study 18005195 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EG)
Number of subjects: 32
Study 18005195 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (PG)
Number of subjects: 32
Study 16637520 — intervention group
Group type: EXPERIMENTAL
Intervention: Terumo X-Coating (PMEA surface coating)
Number of subjects: 30
Study 16637520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobe Smart-X coating (SMA surface coating)
Number of subjects: 30
Study 16637520 — intervention group
Group type: COMPARATOR
Intervention: Terumo noncoated tubing (NCT)
Number of subjects: 30
Study 16637520 — intervention group
Group type: COMPARATOR
Intervention: Cobe noncoated tubing (NCC)
Number of subjects: 30
Study 16637520 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA and PMEA circuits
Number of subjects: 30
Study 14644221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 0.025% eye drops
Number of subjects: 172
Study 14644221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 11030486 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15‐45 mg/day)
Number of subjects: 275
Study 11030486 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (20‐40 mg/day)
Number of subjects: 275
Study 8642153 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based strength training program (Strong-for-Life) for 12 to 15 weeks
Number of subjects: 102
Study 2123370 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone-containing TOC
Number of subjects: 28
Study 2123370 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing TOC
Number of subjects: 28
Study 350232 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg daily
Number of subjects: 135
Study 350232 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg daily
Number of subjects: 135
Study 350232 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg daily
Number of subjects: 135
Study 30757926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicothoracic junction manual therapy
Number of subjects: 22
Study 30757926 — intervention group
Group type: COMPARATOR
Intervention: Upper-cervical manual therapy
Number of subjects: 22
Study 31277991 — intervention group
Group type: EXPERIMENTAL
Intervention: Guy2Guy mHealth HIV prevention program
Number of subjects: 302
Study 27438055 — intervention group
Group type: EXPERIMENTAL
Intervention: Uresta device
Number of subjects: 36
Study 27438055 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal silastic ring
Number of subjects: 36
Study 24819997 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of time at work to exercise
Number of subjects: 188
Study 24819997 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfortable taking time off to exercise
Number of subjects: 188
Study 24819997 — intervention group
Group type: EXPERIMENTAL
Intervention: Too much work
Number of subjects: 188
Study 24819997 — intervention group
Group type: EXPERIMENTAL
Intervention: Job satisfaction and ability to take time off for personal matters
Number of subjects: 188
Study 23429692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 48
Study 23429692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion HCl
Number of subjects: 48
Study 23429692 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 48
Study 21641635 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 51
Study 21641635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 51
Study 21641635 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT plus SLIT
Number of subjects: 51
Study 21641635 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 51
Study 21641635 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT and SLIT
Number of subjects: 51
Study 21641635 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT and SCIT plus SLIT
Number of subjects: 51
Study 21641635 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT
Number of subjects: 51
Study 21641635 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical symptom scores
Number of subjects: 51
Study 19370038 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed lignan complex (543 mg/day in a 4050 mg complex)
Number of subjects: 100
Study 19370038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19370038 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed lignan complex
Number of subjects: 100
Study 16425426 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori eradication therapy
Number of subjects: 259
Study 16425426 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (H pylori-infected)
Number of subjects: 259
Study 12860938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2
Number of subjects: 456
Study 12860938 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2
Number of subjects: 456
Study 10670374 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional module (SIM) on care of child receiving Oxygen Therapy
Number of subjects: 30
Study 2568663 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 40
Study 2568663 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor tranquilizer
Number of subjects: 40
Study 2568663 — intervention group
Group type: COMPARATOR
Intervention: Mental arithmetic (stressor)
Number of subjects: 40
Study 358760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol once daily
Number of subjects: 21
Study 358760 — intervention group
Group type: COMPARATOR
Intervention: Pindolol twice daily
Number of subjects: 21
Study 30558051 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education by Wechat platform plus usual care
Number of subjects: 120
Study 30558051 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 27498443 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amoxicillin and metronidazole (for 7 days)
Number of subjects: 90
Study 27498443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (for 7 days)
Number of subjects: 90
Study 27498443 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 90
Study 25813770 — intervention group
Group type: EXPERIMENTAL
Intervention: Home implantable hemodynamic monitor (IHM) data
Number of subjects: 537
Study 22948012 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month exercise training (n=11)
Number of subjects: 33
Study 22948012 — intervention group
Group type: COMPARATOR
Intervention: Control period (n=10)
Number of subjects: 33
Study 20558433 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD-based educational intervention
Number of subjects: 25
Study 17900989 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (a combination of aerobic and resistance training, three times per week for 24 weeks)
Number of subjects: 21
Study 17900989 — intervention group
Group type: COMPARATOR
Intervention: Control group (no formal exercise program during the 24-week intervention)
Number of subjects: 21
Study 17900989 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 21
Study 15721028 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 24
Study 15721028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14587010 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-pool contrast media (NC100150, 2 ml/kg body weight)
Number of subjects: 12
Study 14587010 — intervention group
Group type: COMPARATOR
Intervention: Conventional X-ray venography (XRV)
Number of subjects: 12
Study 10475476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular assist devices (VADs)
Number of subjects: 19
Study 8708369 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (300 mg/4 weeks)
Number of subjects: 220
Study 8708369 — intervention group
Group type: COMPARATOR
Intervention: Orally trimethoprim‐sulfamethoxazole (320‐1600 mg/day)
Number of subjects: 220
Study 1752294 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg three times a day (t.d.s.)
Number of subjects: 112
Study 1752294 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg three times a day (t.d.s.) with dipyridamole 100 mg t.d.s.
Number of subjects: 112
Study 1752294 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid crystal thermography
Number of subjects: 112
Study 7235320 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide intranasal solution (200 microgram/day) combined with intrabronchial flunisolide (1 mg/day)
Number of subjects: 17
Study 7235320 — intervention group
Group type: COMPARATOR
Intervention: Flunisolide intranasal solution (200 microgram/day) combined with beclomethasone dipropionate bronchial aerosol (400 microgram/day)
Number of subjects: 17
Study 31503037 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (posttetanic count 1 to 2)
Number of subjects: 100
Study 31503037 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block (train-of-four count 1 to 2)
Number of subjects: 100
Study 31503037 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Number of subjects: 100
Study 31503037 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block
Number of subjects: 100
Study 28494850 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Persian medicine preparation of Alcea digitata and Malva sylvestris
Number of subjects: 0
Study 28494850 — intervention group
Group type: COMPARATOR
Intervention: Hypozalix (artificial saliva)
Number of subjects: 0
Study 26388532 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol
Number of subjects: 2546
Study 26388532 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine-alcohol
Number of subjects: 2546
Study 23512915 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR (Interactive Voice Technology)
Number of subjects: 50
Study 23512915 — intervention group
Group type: COMPARATOR
Intervention: WLC (Wait-List Control)
Number of subjects: 50
Study 22092904 — intervention group
Group type: EXPERIMENTAL
Intervention: BEEM rater scale (n = 68)
Number of subjects: 134
Study 22092904 — intervention group
Group type: COMPARATOR
Intervention: McMaster Online Rating of Evidence (MORE) scale (n = 66)
Number of subjects: 134
Study 19232883 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment manoeuvre (RM) followed by a 10 cmH(2)O positive end expiratory pressure (PEEP)
Number of subjects: 26
Study 19232883 — intervention group
Group type: COMPARATOR
Intervention: 10 cmH(2)O positive end expiratory pressure (PEEP)
Number of subjects: 26
Study 17467203 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/DRSP (estradiol 1 mg/drospirenone 2 mg)
Number of subjects: 90
Study 17467203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 14702836 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific antivenom
Number of subjects: 74
Study 14702836 — intervention group
Group type: COMPARATOR
Intervention: Standard antivenom
Number of subjects: 74
Study 11105934 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 3
Study 11105934 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 3
Study 11105934 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3
Study 10167210 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic academic detailer intervention with expert prescribing-system software for physicians.
Number of subjects: 16000
Study 8093363 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T (2 mg/kg/day)
Number of subjects: 41
Study 8093363 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T
Number of subjects: 41